行情

ONCS

ONCS

OncoSec医疗
NASDAQ

实时行情|Nasdaq Last Sale

1.350
+0.100
+8.00%
已收盘, 16:00 03/27 EDT
开盘
1.270
昨收
1.250
最高
1.390
最低
1.230
成交量
7.73万
成交额
--
52周最高
7.50
52周最低
1.039
市值
3,071.63万
市盈率(TTM)
-0.3384
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ONCS价格均价为7.50,最高价位9.00,最低价为6.00。

EPS

ONCS 新闻

更多
  • 各国包机运抗疫物资 包机费飞涨逾一倍
  • 新浪财经 · 50分钟前
  • 欧洲第二大廉航易捷停飞 员工休假两月
  • 新浪财经 · 1小时前
  • 需求暴跌令全球油市无力招架 竟沦落至“倒贴钱”地步
  • 新浪财经 · 1小时前
  • 摩根大通:市场动荡最糟糕阶段已经过去
  • 新浪财经 · 1小时前

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

ONCS 简况

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
展开

微牛提供OncoSec Medical Inc(NASDAQ-ONCS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ONCS股票新闻,以帮助您做出投资决策。